PDF(Pubmed)
Abstract：
Crohn\'s disease (CD) is a chronic, progressive, and destructive disease of the gastrointestinal tract. Although its incidence appears to be stable or decreasing in most countries in the North America and Europe, the incidence is rising rapidly in Asian countries. Immunomodulators and biologics are increasingly used to avoid long-term bowel damage and subsequent disability. Therapeutic drug monitoring facilitates optimizing thiopurines and anti-TNFs use. New biologic agents targeting various pathological pathways of CD are blooming in recent years, and the high cost of biologics and expiration of patents for several biologic agents have driven the utility of biosimilars for CD treatment. Here, the literature regarding the efficacy, safety, and withdrawal of the drugs, as well as the evolution of therapeutic targets will be reviewed.
摘要：
克罗恩病(CD)是一种慢性疾病,进步,和胃肠道的破坏性疾病。尽管在北美和欧洲的大多数国家，其发病率似乎稳定或下降，亚洲国家的发病率正在迅速上升。免疫调节剂和生物制剂越来越多地用于避免长期肠损伤和随后的残疾。治疗药物监测有助于优化硫嘌呤和抗TNF的使用。近年来，针对CD各种病理途径的新生物制剂正在蓬勃发展。生物制剂的高成本和几种生物制剂专利的到期推动了生物仿制药在CD治疗中的应用。这里,关于功效的文献，安全,和戒毒，以及治疗靶点的演变将被审查。
